Topics - Content Areas

Science & Research Lasers & Sources Detectors & Imaging Optics Bio & Life Sciences Laser Processing Fiber Optics Software & Accessories Test & Measurement Executive Forum

Resources and Events

Commentary Magazine Videos White Papers Webinars Events Buyer's Guide PhotonicsNXT Engineering Academy Photonics Market Reports Newsletter Archives

User Tools

Subscribe Advertise About Us Contact Us Privacy Policy Terms & Conditions

https://www.facebook.com/pages/Laser-Focus-World/126899915297

https://www.linkedin.com/showcase/laser-focus-world

https://twitter.com/LaserFocusWorld

https://youtube.com/laserfocusworld

Recent Quotes

My Watchlist

Indicators

LFW Photonics Market Index

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.24 +0.47 (+0.91%)

Streaming Delayed Price Updated: 10:51 AM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying ↗

November 03, 2022

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

October 31, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

10 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 31, 2022

Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Mastercard To $428? Plus This Analyst Slashes PT On Intel ↗

October 31, 2022

Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...

Via Benzinga

Why BioMarin Pharmaceuticals Fell 6.9% on Thursday ↗

October 27, 2022

Investors were expecting better top-line numbers from the company's earnings report.

Via The Motley Fool

Expert Ratings for Biomarin Pharmaceutical ↗

October 13, 2022

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Via Benzinga

One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review ↗

October 13, 2022

Via Benzinga

BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company ↗

October 07, 2022

Via Benzinga

Expert Ratings for Biomarin Pharmaceutical ↗

August 04, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Biomarin Pharmaceutical: Q3 Earnings Insights ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Biomarin Pharmaceutical Q3 Earnings ↗

October 26, 2022

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings ↗

August 04, 2022

Via Benzinga

Analyst Ratings for Biomarin Pharmaceutical ↗

July 13, 2022

Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial ↗

September 12, 2022

Via Benzinga

Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗

September 03, 2022

Neurocrine Biosciences leads five medical stocks showing resilience.

Via Investor's Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate ↗

August 24, 2022

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the...

Via Benzinga

Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart ↗

August 09, 2022

If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Undervalued Biotech Stocks to Buy Before They Boom ↗

July 25, 2022

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

Via InvestorPlace

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them ↗

July 11, 2022

Four pharmaceutical stocks, including three biotech movers, are making big moves.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022 ↗

July 13, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

June 13, 2022

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Via Benzinga

9 Health Care Stocks With Whale Alerts In Today's Session ↗

May 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗

May 09, 2022

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...

Via Benzinga

BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy ↗

April 28, 2022

Via Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

https://www.facebook.com/pages/Laser-Focus-World/126899915297

https://www.linkedin.com/showcase/laser-focus-world

https://twitter.com/LaserFocusWorld

https://youtube.com/laserfocusworld

About Us
Contact Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions